{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:43:26Z","timestamp":1787503406528,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41397-017-0004-2","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T15:44:42Z","timestamp":1514994282000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cost-effectiveness of HLA-DQB1\/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-927X","authenticated-orcid":false,"given":"Fran\u00e7ois R.","family":"Girardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Vernaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pletscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"F. Samer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Villard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016;209:385\u201392.","journal-title":"Br J Psychiatry"},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063\u201371.","journal-title":"Lancet"},{"key":"4_CR3","unstructured":"Drug Safety Communication: FDA modifies monitoring for neutropenia associated with schizophrenia medicine clozapine; approves new shared REMS program for all clozapine medicines. US Food and Drug Administration, www.fda.gov\/Drugs\/DrugSafety. Accessed 30 Oct 2015."},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V86.3.1177.1177","volume":"86","author":"JJ Yunis","year":"1995","unstructured":"Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA associations in clozapine-induced agranulocytosis. Blood 1995;86:1177\u201383.","journal-title":"Blood"},{"issue":"Suppl. 3","key":"4_CR5","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(Suppl. 3):3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1345\/aph.1G396","volume":"40","author":"P Schulte","year":"2006","unstructured":"Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40:683\u20138.","journal-title":"Ann Pharmacother"},{"key":"4_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1176\/appi.ajp.2012.12081036","volume":"170","author":"D Cohen","year":"2013","unstructured":"Cohen D, Monden M. White blood cell monitoring during long-term clozapine treatment. Am J Psychiatry 2013;170:366\u20139.","journal-title":"Am J Psychiatry"},{"key":"4_CR8","first-page":"1055","volume":"44","author":"PF Schulte","year":"2010","unstructured":"Schulte PF, Cohen D, Bogers JP, van Dijk D, Bakker B. A Dutch guideline for the use of clozapine. Aust NZ J Psychiatry 2010;44:1055\u20136.","journal-title":"Aust NZ J Psychiatry"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2217\/14622416.9.8.1101","volume":"9","author":"C Opgen-Rhein","year":"2008","unstructured":"Opgen-Rhein C, Dettling M. Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 2008;9: 1101\u201311.","journal-title":"Pharmacogenomics"},{"key":"4_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5757","volume":"5","author":"JI Goldstein","year":"2014","unstructured":"Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, et al Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun 2014;5:4757.","journal-title":"Nat Commun"},{"key":"4_CR11","first-page":"304","volume":"17","author":"SAJ With de","year":"2017","unstructured":"de With SAJ, Pulit SL, Staal WG, Kahn RS, Ophoff RA. More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharm J 2017;17:304\u201311.","journal-title":"Pharm J"},{"key":"4_CR12","first-page":"395","volume":"17","author":"M Verbelen","year":"2017","unstructured":"Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharm J 2017;17:395\u2013402.","journal-title":"Pharm J"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253\u20138.","journal-title":"JAMA"},{"key":"4_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/hec.903","volume":"13","author":"E Fenwick","year":"2004","unstructured":"Fenwick E, O\u2019Brien BJ, Briggs A. Cost-effectiveness acceptability curves\u2014facts, fallacies and frequently asked questions. Health Econ 2004;13:405\u201315.","journal-title":"Health Econ"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796\u20137.","journal-title":"N Engl J Med"},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2215-0366(14)70245-7","volume":"1","author":"FR Girardin","year":"2014","unstructured":"Girardin FR, Poncet A, Blondon M, Rollason V, Vernaz N, Chalandon Y, et al Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. Lancet Psychiatry 2014;1:55\u201362.","journal-title":"Lancet Psychiatry"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jinf.2016.11.006","volume":"74","author":"H Arefian","year":"2017","unstructured":"Arefian H, Heublein S, Scherag A, Brunkhorst FM, Younis MZ, Moerer O, et al. Hospital-related cost of sepsis: a systematic review. J Infect 2017;74:107\u201317.","journal-title":"J Infect"},{"key":"4_CR18","volume-title":"Micromedex\u00ae 2.0 (electronic version), The red book online","author":"Micromedex\u00ae Solutions.","year":"2015","unstructured":"Micromedex\u00ae Solutions. Micromedex\u00ae 2.0 (electronic version), The red book online. Greenwood Village, CO: Truven Health Analytics; 2015."},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"e1001460","DOI":"10.1371\/journal.pmed.1001460","volume":"10","author":"N Vernaz","year":"2013","unstructured":"Vernaz N, Haller G, Girardin F, Huttner B, Combescure C, Dayer P, et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. PLoS Med. 2013;10:e1001460","journal-title":"PLoS Med"},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2165\/11537300-000000000-00000","volume":"28","author":"I Mavranezouli","year":"2010","unstructured":"Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics 2010;28:1109\u201321.","journal-title":"Pharmacoeconomics"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak 2006;26:410\u201320.","journal-title":"Med Decis Mak"},{"key":"4_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/hec.1612","volume":"20","author":"K Claxton","year":"2011","unstructured":"Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ 2011;20:2\u201315.","journal-title":"Health Econ"},{"key":"4_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/clpt.2013.221","volume":"95","author":"S Crettol","year":"2014","unstructured":"Crettol S, de Leon J, Hiemke C, Eap CB. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 2014;95:254\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"4_CR24","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1371\/journal.pmed.0040209","volume":"4","author":"JJ Swen","year":"2007","unstructured":"Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007;4:e209.","journal-title":"PLoS Med"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1001\/jama.2012.476","volume":"307","author":"CK Cassel","year":"2012","unstructured":"Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA 2012;307:1801\u20132.","journal-title":"JAMA"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2217\/pgs.15.67","volume":"16","author":"M Verbelen","year":"2015","unstructured":"Verbelen M, Lewis CM. How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis? Pharmacogenomics 2015;16:915\u20137.","journal-title":"Pharmacogenomics"},{"key":"4_CR27","first-page":"461","volume":"15","author":"M Verbelen","year":"2015","unstructured":"Verbelen M, Collier DA, Cohen D, MacCabe JH, Lewis CM. Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis. Pharm J 2015;15:461\u20136.","journal-title":"Pharm J"},{"key":"4_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4088\/JCP.09m05527yel","volume":"72","author":"MC Athanasiou","year":"2011","unstructured":"Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, et al Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011;72:458\u201363.","journal-title":"J Clin Psychiatry"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/S0266462312000372","volume":"28","author":"C Henshall","year":"2012","unstructured":"Henshall C, Schuller T, Mardhani-Bayne L. Using health technology assessment to support optimal use of technologies in current practice: the challenge of \u201cdisinvestment\u201d. Int J Technol Assess Health Care 2012;28:203\u201310.","journal-title":"Int J Technol Assess Health Care"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"e0127213","DOI":"10.1371\/journal.pone.0127213","volume":"10","author":"A Poncet","year":"2015","unstructured":"Poncet A, Gencer B, Blondon M, Gex-Fabry M, Combescure C, Shah D, et al Electrocardiographic screening for prolonged QT interval to reduce sudden cardiac death in psychiatric patients: a cost-effectiveness analysis. PLoS ONE 2015;10:e0127213.","journal-title":"PLoS ONE"},{"key":"4_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1056\/NEJMe0809417","volume":"360","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death\u2014how should we manage the risk? New Engl J Med 2009;360:294\u20136.","journal-title":"New Engl J Med"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2215-0366(14)70255-X","volume":"1","author":"E Achilla","year":"2014","unstructured":"Achilla E, McCrone P. Clozapine and patient safety. Lancet Psychiatry 2014;1:8\u20139.","journal-title":"Lancet Psychiatry"},{"key":"4_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568\u201379.","journal-title":"N Engl J Med"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134\u201343.","journal-title":"N Engl J Med"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-017-0004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-017-0004-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-017-0004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T16:59:05Z","timestamp":1684601945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-017-0004-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1038\/s41397-017-0004-2","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]},"assertion":[{"value":"30 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}